Ascendis Pharma A/S
ASND
92 hedge funds and large institutions have $2.49B invested in Ascendis Pharma A/S in 2018 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 8 closing their positions.
338% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 8
104% more capital invested
Capital invested by funds: $1.22B → $2.49B (+$1.27B)
42% more funds holding
Funds holding: 65 → 92 (+27)
17% more funds holding in top 10
Funds holding in top 10: 12 → 14 (+2)
7.93% more ownership
Funds ownership: 83.9% → 91.83% (+7.9%)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$133M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$72.3M |
| 3 |
PA
Perceptive Advisors
New York
|
+$55.2M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$38.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$31.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$75.3M |
| 2 |
VMI
VHCP Management II
New York
|
-$29.6M |
| 3 |
DM
Deerfield Management
New York
|
-$17.2M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$16M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$6.18M |
ASND Hedge Fund Activity: Q1 2018 in Review
92 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2018, worth a combined $2.49B — up 104% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ASND positions and 8 closed out — a net gain of 27 holders — while 27 added to existing stakes and 25 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $133M. The largest seller was RA Capital Management, cutting an estimated $75.3M.
- 92 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2018, up from 65 in Q4 2017.
- Funds reported $2.49B of Ascendis Pharma A/S stock for Q1 2018, up 104% quarter-over-quarter.
- 35 funds opened new Ascendis Pharma A/S positions in Q1 2018 and 8 closed out, a net change of +27 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2018 was T. Rowe Price Associates, an estimated $133M added.
- The largest Ascendis Pharma A/S seller in Q1 2018 was RA Capital Management, an estimated $75.3M sold.
Based on aggregated 13F filings for Q1 2018.